Divi's Laboratories Limited has submitted its quarterly compliance certificate to stock exchanges for the quarter ended March 31, 2026, in accordance with SEBI regulatory requirements. The pharmaceutical company filed the mandatory certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Submission

The compliance certificate was submitted to both major Indian stock exchanges where the company's shares are listed. Company Secretary & Compliance Officer M. Satish Choudhury signed and submitted the documentation on April 06, 2026.

Certificate Confirmation Details

KFin Technologies Limited, serving as the Registrar & Share Transfer Agent, provided confirmation regarding the dematerialization process for the quarter. Deputy Vice President Ganesh Chandra Patro signed the certificate on April 02, 2026, confirming compliance with regulatory requirements.

The certificate confirms several key operational aspects:

• Securities received from depository participants for dematerialization were properly confirmed to depositories
• All securities have been listed on BSE Limited and National Stock Exchange of India Limited
• Security certificates received for dematerialization were mutilated and cancelled after verification
• Depository names were substituted in the register of members within the mandated 15-day period

Stock Exchange Communication

The submission was made to both primary stock exchanges where Divi's Laboratories shares are traded. The company maintains its listing on National Stock Exchange of India Limited and BSE Limited, ensuring compliance across all trading platforms.

This quarterly submission represents standard regulatory compliance for listed companies, ensuring transparency in securities handling and depository operations. The certificate validates that all dematerialization processes during the quarter were conducted in accordance with SEBI guidelines and exchange requirements.

Divi's Laboratories Limited has received a draft assessment order from the Income Tax Authority proposing substantial tax additions for the financial year 2022-23. The pharmaceutical company disclosed this development through a regulatory filing dated March 21, 2026, in compliance with SEBI listing regulations.

Draft Assessment Order Details

The draft order, issued under Section 144C(1) of the Income Tax Act, 1961, was dated March 20, 2026, and received by the company on March 21, 2026. The communication originated from the Assistant Commissioner of Income Tax, Central Circle-2(1), Hyderabad.

Nature of Proposed Adjustments

The draft assessment order proposes additions and disallowances amounting to ₹570.51 crores with respect to the company's returned income. The proposed adjustments primarily stem from:

• Transfer pricing adjustments on specified domestic transactions
• Corporate tax adjustments

These adjustments would result in additional income tax liability on the upward adjustment in income as specified in the draft order.

Penalty Implications

According to the draft order, penalty proceedings under Section 270A of the Income Tax Act, 1961, will be initiated separately for alleged under-reporting of income in respect of the proposed additions. This could potentially result in additional financial implications beyond the primary tax liability.

Company's Response Strategy

Divi's Laboratories has indicated that it is currently evaluating the draft assessment order in detail. The company has expressed its intention to file an appeal against the proposed adjustments with the appropriate authority within the stipulated timeframe. This approach suggests the company disagrees with the tax authority's assessment and believes it has grounds to challenge the proposed additions.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically under sub-para 8 of Para B of Part A Schedule III. This regulatory requirement ensures transparency regarding material developments that could impact the company's financial position and investor interests.